Gout News: Breaking Gout News, Comments and Articles. - Page: 3

Research findings could lead to development of new drugs for gout treatment

Findings from a Loyola University Chicago Stritch School of Medicine study could lead to the development of new drugs to treat gout.

Study could aid development of new drugs to treat gout

Findings from a Loyola University Chicago Stritch School of Medicine study could lead to the development of new drugs to treat gout. The study, led by Liang Qiao, MD, and his colleagues and collaborators, was published March 19 in the journal Nature...

Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results

BRIDGEWATER, N.J., March 19, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months and full year ended December 31, 2012.  Savient ended the quarter with approximately $96.3 million in cash and short-term investments, a decrease of $19.9 million for the quarter. Net sales of KRYSTEXXA were $4.7 million for the fourth qua...

Omni Bio announces favorable results in its lead recombinant molecule

Omni Bio Pharmaceutical Inc. (Denver) Announced favorable results for its recombinant molecule, Fc-AAT. According to data presented on the therapeutic applications of Fc-AAT in gout at the 4th European Workshop on Crystals in Human Diseases in Paris,...

Omni Bio Announces First Results for Its Lead Recombinant Molecule

DENVER, CO -- (Marketwire) -- 03/15/13 -- Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced the first disclosure of important results for its recombinant molecule, Fc-AAT...

New educational videos from the Gout & Uric Acid Education Society highlight key insights from the ACR Guidelines on gout diagnosis and treatment

PITTSBURGH, March 12, 2013 /PRNewswire/ -- The Gout & Uric Acid Education Society (GUAES) has added six new educational videos for patients and medical professionals to its library of popular educational videos on gout, highlighting the society's most important takeaways from the recently released American College of Rheumatology (ACR) Guidelines on Gout Diagnosis and Treatment. Available unde...

RCGP and Arthritis Research UK launch new e-learning module on Musculoskeletal Care

Musculoskeletal Care (MSK) is the focus of a new e-learning course launched this week by the Royal College of General Practitioners (RCGP) in collaboration with Arthritis Research UK. The module is the latest addition to the RCGP’s rapidly-expanding Online Learning Environment (OLE) and it is free to all healthcare professionals - not just members of the College. It aims to improve GPs’ and...

Gout drug offers hope for heart disease patients

(Medical Xpress)—Research at the University of Dundee has shown than an old, inexpensive anti-gout drug has benefits for heart disease sufferers and has the potential to one day help prevent heart disease, sudden deaths and strokes.

Novartis' Ilaris approved in EU as gout treatment

Novartis' Ilaris approved in EU as gout treatment

Novartis receives EU approval for Ilaris® in patients suffering acute gouty arthritis attacks who cannot gain relief from current treatments

Novartis International AG / Novartis receives EU approval for Ilaris® in patients suffering acute gouty arthritis attacks who cannot gain relief from current treatments . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Ilaris® is the first biologic approved in the EU for symptomatic pain relief in a gouty arthritis indic...

Canakinumab gets EU approval for treatment of gout

A new treatment called canakinumab (brand name Ilaris) has been granted EU marketing approval in patients with acute gout attacks that do not respond to other existing therapies.Canakinumab is an injectable biologic therapy that works by targeting a protein called interleukin-1 beta (IL-1 beta), which plays a key role in the inflammation seen in people with gout.The drug is delivered via a single...

Arthritis Compromises Daily Function and Stirs Dependence Fears

Survey finds that this common ailment has a big impact on quality of life ROCKLIN, Calif., Feb. 27, 2013 /PRNewswire-USNewswire/ -- Most people expect some aches and pains due to arthritis as they age, but a new survey by the American Chronic Pain Association (ACPA) finds that many with arthritis face significant disability due to the condition.  In addition, those with arthritis live wi...

Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013

BRIDGEWATER, N.J., Feb. 26, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's fourth quarter and year-end 2012 financial results will be released prior to the market open on Tuesday, March 19, 2013.  Savient's executive management will host a conference call beginning at 9:00 a.m. Eastern Time on March 19, 2013, to discuss these results...

Review suggests acupuncture an effective complementary treatment for gout

Research published in the journal Rheumatology suggests that acupuncture is an effective complementary treatment for patients suffering from gout.The painful condition is characterised by a build-up of uric acid crystals in the joints and tissues that can lead to inflammation, intense pain and flaky skin over affected areas. Often, it affects the joint of the big toe.Colleagues at Kyung Hee Univer...

Advanced Imaging in the Diagnosis and Management of Gout

Learn more on the application of advanced imaging tools in gout -- and how they can impact the diagnosis and management of this disease. Postgraduate Medical Journal

Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret® (anakinra) in the U.S.

CONTACT: Swedish Orphan Biovitrum (Sobi) ABAlan RaffenspergerChief Operating Officer+46 8 697 20 90 Savient Pharmaceuticals, Inc.              John P. HamillSenior Vice President and Chief Financial Officerinformation@savient.com (732) 418-9300 Burns McClellan Caitlyn Murphycmurphy@burnsmc.com(212) 213-0006 Stockholm, Sweden / Bridgewater, New Jersey, February 19, 201...

Horsemeat scandal – latest update

What is the latest news? On February 14 the Food Standards Agency (FSA) released a statement that they had detected the presence of phenylbutazone (bute) in horses slaughtered in the UK. They tested a total of 206 horse carcasses between January 30 and February 7 2013. Of these, eight tested positive for the drug. Of these eight: Six were sent to France and may have entered the food chain....

Horsemeat investigation: latest update

On February 14 the Food Standards Agency (FSA) released a statement that it had detected the presence of phenylbutazone (bute) in horses slaughtered in the UK. They tested a total of 206 horse carcasses between January 30 and February 7 2013. Of these, eight tested positive for the drug. Of these eight: Six were sent to France and may have entered the food chain. The remaining two did n...

Crystal arthritis: Is HLAB genotyping the future of gout pharmacogenomics?

Pharmacogenomic advances have increased understanding of allopurinol-associated severe cutaneous adverse reactions (SCARs), demonstrating that HLAB*5801 is a strong risk factor for their development. In some populations, all patients with allopurinol...

Official advice about horsemeat safety released

Concerns have been raised about the safety of horsemeat in the wake of the contaminated beef scandal. The Daily Mail asks, 'Is horsemeat harmful after all?', while The Guardian states that, 'Contaminated horsemeat could harm health, warns environment secretary.' Horsemeat has been confirmed to have been present in several products labelled and sold as "beef". Horsemeat in itself is not a...

Gout 'common' among patients with kidney disease

Gout is common among people with chronic kidney disease and becomes increasingly prevalent as the severity of kidney disease rises, a new study has shown.About 1.4 per cent of adults in the UK are affected by gout, which is the most common type of inflammatory arthritis.The disease develops when the body is unable to flush out excess uric acid or urate, causing it to build up and form sodium urate...

Rheumatology Therapeutics Market Set to Witness Modest Growth

GBI Research has released its latest research on, “Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth”, The report provides insights into the rheumatology therapeutics market forecasts until 2018 and examines global treatment usage patterns for various rheumatology disorders. The rheumato...

BioCryst to Announce Fourth Quarter & 2012 Financial Results on February 19, 2013

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its fourth quarter and full year 2012 financial results will be released on Tuesday, February 19, 2013. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update on the Company’s programs. The call will be led by

Treatment for gout

According to a recent study of doctors' practice records, NHS hospital admissions for gout have "doubled" in ten years to reach 4,400 cases annually.Around 800,000 people in Britain are estimated to have the disease. George Nuki, of the UK Gout Society and professor emeritus of rheumatology at Edinburgh University, said: "It’s now the most common chronic inflammatory rheumatic disease; more comm...

NICE rejects Savient's gout drug due to 'very high cost' and risk

NICE, the health technology appraisal institute for England and Wales, has issued draft guidance rejecting Savient's gout treatment Krystexxa (pegloticase) on the basis of its "very high cost compared with the known benefit". Krystexxa is.....